SCHEMBL260186

SCHEMBL260186

CC(C(=O)O)n1c(=O)n2c3c(c(Cl)nc(Cl)c31)NC(=O)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028810 0.75 PTGDR2 (0.32) —
SCHEMBL259895 0.67 CALCRL (0.42) —
SCHEMBL7862920 0.59 ALDH1A1 (0.42) —
SCHEMBL11605673 0.55 CYP1A2 (0.48) —
SCHEMBL6526383 0.55 CSNK2A2 (0.37) —
SCHEMBL2032749 0.55 CSNK2A2 (0.43) —
SCHEMBL3507651 0.55 CSNK2A2 (0.43) —
SCHEMBL10517911 0.55 MAPT (0.33) —
SCHEMBL7336986 0.55 KDM4E (0.45) —
SCHEMBL11397353 0.53 ALDH1A1 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 — — US disclosed
US-8133891-B2 Tricyclic anilide spirolactam CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-03-13 — — US disclosed
Send feedback